ES2255054T3 - Expresion del gen de la proteina neurofilamentosa y deteccion de la enfermedad de alzheimer. - Google Patents
Expresion del gen de la proteina neurofilamentosa y deteccion de la enfermedad de alzheimer.Info
- Publication number
- ES2255054T3 ES2255054T3 ES94915396T ES94915396T ES2255054T3 ES 2255054 T3 ES2255054 T3 ES 2255054T3 ES 94915396 T ES94915396 T ES 94915396T ES 94915396 T ES94915396 T ES 94915396T ES 2255054 T3 ES2255054 T3 ES 2255054T3
- Authority
- ES
- Spain
- Prior art keywords
- ntp
- protein
- molecule
- dna
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/474—Pancreatic thread protein; Reg protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5055993A | 1993-04-20 | 1993-04-20 | |
| US50559 | 1993-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2255054T3 true ES2255054T3 (es) | 2006-06-16 |
Family
ID=21965952
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94915396T Expired - Lifetime ES2255054T3 (es) | 1993-04-20 | 1994-04-20 | Expresion del gen de la proteina neurofilamentosa y deteccion de la enfermedad de alzheimer. |
| ES04076254T Expired - Lifetime ES2312913T3 (es) | 1993-04-20 | 1994-04-20 | Expresion genica de la proteina de la cadena neural y deteccion de la enfermedad de alzheimer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04076254T Expired - Lifetime ES2312913T3 (es) | 1993-04-20 | 1994-04-20 | Expresion genica de la proteina de la cadena neural y deteccion de la enfermedad de alzheimer. |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP1564293B9 (https=) |
| JP (2) | JP3513859B2 (https=) |
| KR (1) | KR100392244B1 (https=) |
| AT (2) | ATE312348T1 (https=) |
| CA (1) | CA2161097A1 (https=) |
| DE (2) | DE69435136D1 (https=) |
| DK (2) | DK1564293T3 (https=) |
| ES (2) | ES2255054T3 (https=) |
| NZ (1) | NZ266072A (https=) |
| PT (1) | PT1564293E (https=) |
| WO (1) | WO1994023756A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
| AU1110297A (en) * | 1995-12-12 | 1997-07-03 | Kyowa Hakko Kogyo Co. Ltd. | Novel dnas, novel polypeptides and novel antibodies |
| US5936078A (en) * | 1995-12-12 | 1999-08-10 | Kyowa Hakko Kogyo Co., Ltd. | DNA and protein for the diagnosis and treatment of Alzheimer's disease |
| CA2282729A1 (en) | 1997-02-26 | 1998-09-03 | The General Hospital Corporation | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease |
| US7226730B1 (en) | 1997-02-26 | 2007-06-05 | The General Hospital Corporation | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease |
| EP1006794B1 (en) | 1997-03-12 | 2007-11-28 | Robert W. Esmond | A method for treating or preventing alzheimer's disease |
| DK1392347T3 (da) * | 2001-05-16 | 2005-12-12 | Nymox Corp | Fremgangsmåde til at forhindre celledöd med anvendelse af segmenter af neurale trådproteiner |
| EP1541166B1 (en) * | 2001-05-16 | 2007-12-19 | Nymox Corporation | Preventing cell death using segments of neural thread proteins |
| US6770797B2 (en) * | 2001-06-01 | 2004-08-03 | Rhode Island Hospital | Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid |
| US7317077B2 (en) | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| EP1714979A3 (en) * | 2001-11-16 | 2007-04-25 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| EP1994152B1 (en) | 2006-02-28 | 2012-12-12 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US20080027005A1 (en) * | 2006-07-31 | 2008-01-31 | Paul Averback | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| US10183058B2 (en) | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
| US10172910B2 (en) | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
| CN119173632A (zh) * | 2022-05-10 | 2024-12-20 | 豪夫迈·罗氏有限公司 | 靶向cfp-elk1基因间区域的反义寡核苷酸 |
| AU2024261891A1 (en) * | 2023-04-27 | 2025-09-25 | Siemens Healthcare Diagnostics Inc. | High-sensitivity assay for serum neurofilament light chain |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990006993A1 (en) * | 1988-12-21 | 1990-06-28 | The General Hospital Corporation | Method of detecting neurological disease or dysfunction |
-
1994
- 1994-04-20 KR KR1019950704656A patent/KR100392244B1/ko not_active Expired - Fee Related
- 1994-04-20 DK DK04076254T patent/DK1564293T3/da active
- 1994-04-20 DE DE69435136T patent/DE69435136D1/de not_active Expired - Fee Related
- 1994-04-20 DK DK94915396T patent/DK0697893T3/da active
- 1994-04-20 EP EP04076254A patent/EP1564293B9/en not_active Expired - Lifetime
- 1994-04-20 JP JP52355694A patent/JP3513859B2/ja not_active Expired - Fee Related
- 1994-04-20 PT PT04076254T patent/PT1564293E/pt unknown
- 1994-04-20 DE DE69434844T patent/DE69434844T2/de not_active Expired - Fee Related
- 1994-04-20 ES ES94915396T patent/ES2255054T3/es not_active Expired - Lifetime
- 1994-04-20 WO PCT/US1994/004321 patent/WO1994023756A1/en not_active Ceased
- 1994-04-20 CA CA002161097A patent/CA2161097A1/en not_active Abandoned
- 1994-04-20 NZ NZ266072A patent/NZ266072A/en not_active IP Right Cessation
- 1994-04-20 AT AT94915396T patent/ATE312348T1/de not_active IP Right Cessation
- 1994-04-20 ES ES04076254T patent/ES2312913T3/es not_active Expired - Lifetime
- 1994-04-20 EP EP94915396A patent/EP0697893B1/en not_active Expired - Lifetime
- 1994-04-20 AT AT04076254T patent/ATE406444T1/de not_active IP Right Cessation
-
2003
- 2003-10-01 JP JP2003343063A patent/JP2004097227A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT1564293E (pt) | 2008-12-02 |
| ATE312348T1 (de) | 2005-12-15 |
| EP1564293B9 (en) | 2009-08-19 |
| KR100392244B1 (ko) | 2003-11-28 |
| AU674581B2 (en) | 1997-01-02 |
| DK0697893T3 (da) | 2006-02-20 |
| WO1994023756A1 (en) | 1994-10-27 |
| CA2161097A1 (en) | 1994-10-27 |
| JPH08509808A (ja) | 1996-10-15 |
| DE69434844D1 (de) | 2006-10-19 |
| EP0697893B1 (en) | 2005-12-07 |
| DE69435136D1 (de) | 2008-10-09 |
| DE69434844T2 (de) | 2006-12-14 |
| ATE406444T1 (de) | 2008-09-15 |
| EP1564293A1 (en) | 2005-08-17 |
| NZ266072A (en) | 1997-07-27 |
| JP2004097227A (ja) | 2004-04-02 |
| EP1564293B1 (en) | 2008-08-27 |
| ES2312913T3 (es) | 2009-03-01 |
| AU6666994A (en) | 1994-11-08 |
| EP0697893A4 (en) | 1996-12-18 |
| EP0697893A1 (en) | 1996-02-28 |
| DK1564293T3 (da) | 2009-01-12 |
| JP3513859B2 (ja) | 2004-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2255054T3 (es) | Expresion del gen de la proteina neurofilamentosa y deteccion de la enfermedad de alzheimer. | |
| US5830670A (en) | Neural thread protein gene expression and detection of Alzheimer's disease | |
| AU641376B2 (en) | Method of detecting neurological disease or dysfunction | |
| WO1996015272A9 (en) | Neural thread protein gene expression and detection of alzheimer's disease | |
| WO2001023426A2 (en) | Hypoxia-related human genes, proteins, and uses thereof | |
| US20070199080A1 (en) | Diagnostic and therapeutic use of F-box proteins for Alzheimer's disease and related neurodegenerative disorders | |
| US20080301821A1 (en) | Diagnostic and Therapeutic use of a Plasma Membrane Atpase | |
| US20060040315A1 (en) | Methods for detecting neurological disorders | |
| US20040157225A1 (en) | Diagnostic and therapeutic use of a nuclear restricted protein for alzheimer's disease and related neurodegenerative disorders | |
| AU674581C (en) | Neural thread protein gene expression and detection of alzheimer's disease | |
| US7364847B2 (en) | Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant | |
| US6331412B1 (en) | Methods and compounds for modulating male fertility | |
| US20070269800A9 (en) | Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases |